Possible clinical implications of the Cardiac Insufficiency Bisoprolol (CIBIS) III trial

British Journal of Cardiology

Volumn 12, Issue 6, 2005, Pages 448-454

  Willenheimer, Ronnie ^a   Silke, Bernard ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Beta Blockers; Bisoprolol; Enalapril; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; VASODILATOR AGENT;

CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; MONOTHERAPY; MORTALITY; POPULATION RESEARCH; PRACTICE GUIDELINE; RANDOMIZATION; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 29744456244     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-35.
2. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking? J Am Coll Cardiol 1997;30: 1589-97.
3. Huirkuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.
4. Lane RE, Cowie MR, Chow AW. Prediction and prevention of sudden cardiac death in heart failure. Heart 2005;91:674-80.
5. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999;353:9-13.
6. MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-07.
7. Packer M, Coats AJ, Fowler MB et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
8. Krum H. β-adrenoceptor blockers in chronic heart failure - a review. Br J Clin Pharmacol 1997;44:111-18.
9. Heidenreich PA, Lee TT, Massie BM. Effect of beta blockade on mortality in patients with heart failure: a meta analysis of randomized clinical trials. J Am Coll Cardial 1997;30:27-34.
10. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double blind, placebo controlled, randomized trials. Circulation 1998;98:1184-91.
11. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999;1:41-5.
12. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE inhibitor Trials. JAMA 1995;273:1450-6.
13. Willenheimer R, Erdmann E, Follath F et al. on behalf of the CIBIS-III investigators. Comparison of treatment initiation with bisoprolol versus enalapril in chronic heart failure patients: rationale and design of CIBIS-III. Eur J Heart Fail 2004;6:493-500.
14. Swedberg K, Cleland J, Dargie H et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur HeartJ 2005;26:1115-40.
15. Hunt SA, Baker DW, Chin MH et al. American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
16. Cleland JG, Cohen-Solal A, Aguilar JC et al. IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002;360:1631-9.
17. Davies M, Hobbs F, Davis R et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-44.
18. Komajda M, Lapuerta P, Hermans N et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005;26:1653-9.
19. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich) 2003;5:58-63.
20. Cleland JG, Daubert JC, Erdmann E et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
21. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an anti hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
22. Wikstrand J, Hjalmarson A, Waagstein F et al. MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-8.
23. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Eur Heart J 2003;24:552-9.
24. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 2003;22:169-86.
25. Anonymous. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 199 1;325:293-302.
26. Packer M. Pathophysiology of heart failure. Lancet 1992;340:88-95.
27. Campbell DJ, Aggarwal A, Esler M, Kaye D. Beta blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001;358:1609-10.
28. Teisman AC, van Veldhuisen DJ, Boomsma F et al. Chronic beta blocker treatment in patients with advanced heart failure. Effects on neurohormones. Int J Cardiol 2000;73:7-14.
29. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469-79.